Ardent Health (NYSE:ARDT – Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.2354 per share and revenue of $1.60 billion for the quarter. Ardent Health has set its FY 2026 guidance at 0.780-1.150 EPS. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 10:00 AM ET.
Ardent Health (NYSE:ARDT – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.06). The business had revenue of $1.62 billion during the quarter, compared to analysts’ expectations of $1.59 billion. On average, analysts expect Ardent Health to post $0.96 EPS for the current fiscal year and $1.20 EPS for the next fiscal year.
Ardent Health Price Performance
Shares of NYSE:ARDT traded up $0.18 during mid-day trading on Wednesday, reaching $12.01. 15,983 shares of the company’s stock were exchanged, compared to its average volume of 450,868. Ardent Health has a twelve month low of $7.71 and a twelve month high of $15.48. The business’s fifty day moving average price is $11.08 and its 200-day moving average price is $9.92.
Wall Street Analyst Weigh In
Several brokerages have recently commented on ARDT. BMO Capital Markets started coverage on Ardent Health in a research note on Tuesday, September 22nd. They issued a “market perform” rating and a $11.00 target price for the company. Royal Bank Of Canada raised their price target on shares of Ardent Health from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Monday, August 10th. Wall Street Zen lowered shares of Ardent Health from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings upgraded Ardent Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, October 6th. Finally, Truist Financial raised their price objective on shares of Ardent Health from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Seven research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $12.79.
Read Our Latest Report on Ardent Health
About Ardent Health
Ardent Health is a U.S. healthcare services company that operates hospitals, outpatient facilities and physician practices. Its services include emergency and acute care, surgery, cardiology, orthopedics, oncology, women’s health, behavioral health, rehabilitation, imaging and other specialty and primary care offerings.
The company serves patients through regional health networks and hospital campuses primarily in Texas, Oklahoma, New Mexico and other U.S. markets. In addition to hospital-based care, Ardent operates outpatient clinics, urgent care locations and other facilities designed to provide services across different stages of the patient-care process.
Ardent Health was founded in 2001 and became a publicly traded company on the New York Stock Exchange in 2024.
See Also
- Five stocks we like better than Ardent Health
- Palantir’s Q3 Bar Is Higher Than It Looks: 3 Numbers to Watch
- Johnson Controls Beats the Heat in AI Data Centers
- 3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead
- Is United Parcel Service Finally Turning the Corner?
Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.
